Hikma patents expiration
1. Combogesic Iv patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11446266 | HIKMA | Combination composition |
Oct, 2031
(7 years from now) | |
| US11389416 | HIKMA | Aqueous formulation comprising paracetamol and ibuprofen |
Jul, 2035
(11 years from now) | |
| US11213498 | HIKMA | Aqueous formulation comprising paracetamol and ibuprofen |
Jan, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 17, 2026 |
Drugs and Companies using ACETAMINOPHEN; IBUPROFEN SODIUM ingredient
Market Authorisation Date: 17 October, 2023
Treatment: Method of treating moderate to severe pain in adults as an adjunct to opioid analgesics
Dosage: SOLUTION;INTRAVENOUS
COMBOGESIC IV family patents
2. Immphentiv patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11471400 | HIKMA | Phenylephrine hydrochloride ready-to-use solution |
Aug, 2036
(12 years from now) | |
| US11213480 | HIKMA | Phenylephrine hydrochloride ready-to-use solution |
Sep, 2036
(12 years from now) | |
Drugs and Companies using PHENYLEPHRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 09 March, 2023
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
IMMPHENTIV family patents
3. Kloxxado patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10973814 | HIKMA | Liquid naloxone spray |
Aug, 2034
(10 years from now) | |
| US10722510 | HIKMA | Liquid naloxone spray |
Aug, 2034
(10 years from now) | |
| US11617713 | HIKMA | Liquid naloxone spray |
Aug, 2034
(10 years from now) | |
| US11628139 | HIKMA | Liquid naloxone spray |
Aug, 2034
(10 years from now) | |
| US11135155 | HIKMA | Liquid naloxone spray |
Aug, 2034
(10 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 29 April, 2021
Treatment: Use of naloxone for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients
Dosage: SPRAY;NASAL
KLOXXADO family patents
4. Levothyroxine Sodium patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11154498 | HIKMA | Stabilized liquid formulation of levothyroxine |
Jul, 2036
(12 years from now) | |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 17 May, 2021
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
LEVOTHYROXINE SODIUM family patents
5. Xopenex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5362755 | HIKMA | Method for treating asthma using optically pure (R)-albuterol |
Mar, 2013
(11 years ago) | |
| US5547994 | HIKMA | Method for treating asthma using optically pure R(-) albuterol |
Aug, 2013
(10 years ago) | |
| US6451289 | HIKMA | Albuterol formulations |
Mar, 2021
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-151) | Jan 22, 2018 |
Drugs and Companies using LEVALBUTEROL HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 2002
Treatment: Treatment or prevention of bronchospasm
Dosage: SOLUTION;INHALATION
XOPENEX family patents